Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
BeerYaakov Mental Health Center Lundbeck Israel |
---|---|
Information provided by: | BeerYaakov Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00456937 |
SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Escitalopram |
Phase IV |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Beer Yaakov MHC | |
Beer Yaakov, Israel, 70350 |
Principal Investigator: | Rafael Octavio Stryjer, M.D. | Beer Yaakov Mental Health Center |
Responsible Party: | Beer-Yaakov MHC ( Dr Rafael Stryjer ) |
Study ID Numbers: | Escitalopram-173CTIL |
Study First Received: | December 3, 2006 |
Last Updated: | January 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00456937 History of Changes |
Health Authority: | United States: Food and Drug Administration; Israel: Israeli Health Ministry Pharmaceutical Administration |
Neurotransmitter Agents Cholinergic Antagonists Psychotropic Drugs Cholinergic Agents Serotonin Uptake Inhibitors Citalopram Serotonin Schizophrenia Muscarinic Antagonists |
Anxiety Disorders Mental Disorders Psychotic Disorders Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Dexetimide Antidepressive Agents Obsessive-Compulsive Disorder Schizophrenia and Disorders with Psychotic Features |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents Schizophrenia Mental Disorders Therapeutic Uses Dexetimide |
Antidepressive Agents, Second-Generation Schizophrenia and Disorders with Psychotic Features Obsessive-Compulsive Disorder Antidepressive Agents Citalopram Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Anxiety Disorders Autonomic Agents Peripheral Nervous System Agents Central Nervous System Agents |